Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grape King Bio's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$3,539 Mil.
Grape King Bio's quarterly Ending Cash Position
declined
from Dec. 2025 (NT$4,165 Mil) to Mar. 2026 (NT$3,976 Mil) and
declined
from Mar. 2026 (NT$3,976 Mil) to Jun. 2026 (NT$3,539 Mil).
Grape King Bio's annual Ending Cash Position
declined
from Dec. 2023 (NT$4,819 Mil) to Dec. 2024 (NT$4,343 Mil) and
declined
from Dec. 2024 (NT$4,343 Mil) to Dec. 2025 (NT$4,165 Mil).
Grape King Bio Ending Cash Position Historical Data
* Premium members only.
The historical data trend for Grape King Bio's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
Grape King Bio's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of NT$3,539 Mil mean?
Grape King Bio (TPE:1707) has a Ending Cash Position of NT$3,539 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Grape King Bio and its competitors.
Is Grape King Bio's Ending Cash Position too high?
Grape King Bio's current Ending Cash Position is NT$3,539 Mil. Overall, Grape King Bio has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's Ending Cash Position compare to ZTS?
Grape King Bio's Ending Cash Position of NT$3,539 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Grape King Bio and its competitors. Grape King Bio's current Ending Cash Position is NT$3,539 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$134.09, compared to a current price of NT$90.20 — trading 32.7% below its estimated fair value. The current Ending Cash Position is NT$3,539 Mil. Grape King Bio's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current Ending Cash Position is NT$3,539 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grape King Bio (TPE:1707) Overvalued in 2026?
Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued.
The current stock price of NT$90.20 is trading 32.7% below its estimated GF Value™ of NT$134.09.
GuruFocus considers Grape King Bio to be Significantly Undervalued.
Key valuation signals for TPE:1707:
Ending Cash Position: NT$3,539 Mil
GF Value™: NT$134.09 vs. price of NT$90.20 (32.7% below fair value)
No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
81GF Score
Get the complete analysis for TPE:1707
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1707 has been successfully added to your 
